Sprint Bioscience Q1: A highly intense period - Redeye
Bildkälla: Stockfoto

Sprint Bioscience Q1: A highly intense period - Redeye

2025 has turned out to be a very intense period so far, including a SEK 23m fundraising, publications, a strategic review, the announced discontinued Day One collaboration and a subsequent review, including reducing the operational costs. The proactive approach after the Day One announcement is positive, and there is pressure to secure new partners shortly.

2025 has turned out to be a very intense period so far, including a SEK 23m fundraising, publications, a strategic review, the announced discontinued Day One collaboration and a subsequent review, including reducing the operational costs. The proactive approach after the Day One announcement is positive, and there is pressure to secure new partners shortly.
Börsvärldens nyhetsbrev